A state jury in Georgia directed Bayer, the parent company of Monsanto, to pay more than $2.1 billion in damages to a man who ...

The death of former U.S. Rep. Mia Love has brought renewed attention to an aggressive form of brain cancer that killed her at ...

Cancer research has had bipartisan support. But Trump administration budget cuts and delays threaten to reverse progress of ...

BDC-3042 Phase 1 clinical trial fully enrolled the highest dose cohort with no dose-limiting toxicities (DLTs), results will ...

B-cell acute lymphoblastic leukemia (B-ALL) is a life-threatening and highly aggressive form of blood cancer. It is the most common childhood cancer, making up 35% of pediatric cancer cases, but it ...

Experimental therapy uses a modified virus to boost immunity and make anti-tumour treatments more effective, according to ...

A fundamental shake-up of how we screen women for breast cancer could save more lives from the disease. Here are some options ...

The FDA cleared the investigational new drug (IND) application for EVM14. EVM14 is an off-the-shelf tumor-associated antigen ...

The following is a summary of "Redefining Clinical Trial Strategic Design to Support Drug Approval in Medical Oncology” ...

Contemplated merger with Decoy Therapeutics progressing as planned; upon closing, combined company expected to accelerate clinical development of ...

Ractigen Therapeutics, a clinical-stage biopharmaceutical company pioneering small activating RNA (saRNA) therapeutics, today announced the presentation of positive preliminary data from its ongoing ...

The AUR87A study found that urine collected biomarkers could accurately predict recurrence of kidney cancer in post-surgery ...